Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience

Leuk Lymphoma. 2020 Dec;61(12):3014-3017. doi: 10.1080/10428194.2020.1795161. Epub 2020 Jul 28.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bendamustine Hydrochloride
  • Brentuximab Vedotin
  • Hodgkin Disease* / drug therapy
  • Humans
  • Immunoconjugates*
  • Neoplasm Recurrence, Local / drug therapy
  • Progression-Free Survival

Substances

  • Immunoconjugates
  • Brentuximab Vedotin
  • Bendamustine Hydrochloride